E6742

DRUG4 trials

Sponsors

Eisai Inc., Eisai Co., Ltd.

Conditions

Healthy ParticipantsHealthy VolunteersLupus Erythematosus, SystemicSystemic Lupus Erythematosus

Phase 1

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

CompletedNCT03082235

Eisai Inc.Healthy Participants

Start: 2017-03-03End: 2017-10-11Updated: 2018-09-07

A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants

CompletedNCT04683185

Eisai Co., Ltd.Healthy Volunteers

Start: 2020-12-28End: 2021-06-21Updated: 2021-07-20

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants

CompletedNCT05278663

Eisai Co., Ltd.Lupus Erythematosus, Systemic

Start: 2022-04-14End: 2023-09-04Updated: 2023-09-29

Phase 2

A Study of E6742 in Participants With Systemic Lupus Erythematosus

RecruitingNCT07515014

Eisai Co., Ltd.Systemic Lupus Erythematosus

Start: 2026-03-31End: 2029-03-01Target: 256Updated: 2026-08-21

Related Papers

Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

RMD Open2024-09-0111 citations

A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration.

2023-09-297 citations